Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund decreased its position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 5.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 114,349 shares of the company’s stock after selling 6,441 shares during the period. New York State Common Retirement Fund’s holdings in Aerie Pharmaceuticals were worth $1,304,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of AERI. Russell Investments Group Ltd. grew its position in shares of Aerie Pharmaceuticals by 75.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 89,699 shares of the company’s stock worth $1,435,000 after acquiring an additional 38,527 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Aerie Pharmaceuticals by 7.7% in the 2nd quarter. Swiss National Bank now owns 98,000 shares of the company’s stock worth $1,569,000 after purchasing an additional 7,000 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of Aerie Pharmaceuticals by 7.7% in the 2nd quarter. Sei Investments Co. now owns 30,215 shares of the company’s stock worth $479,000 after purchasing an additional 2,163 shares during the last quarter. HighTower Advisors LLC lifted its holdings in shares of Aerie Pharmaceuticals by 9.9% in the 2nd quarter. HighTower Advisors LLC now owns 27,222 shares of the company’s stock worth $437,000 after purchasing an additional 2,441 shares during the last quarter. Finally, Citigroup Inc. lifted its holdings in shares of Aerie Pharmaceuticals by 5.8% in the 2nd quarter. Citigroup Inc. now owns 1,240,824 shares of the company’s stock worth $19,866,000 after purchasing an additional 67,658 shares during the last quarter.

Shares of Aerie Pharmaceuticals stock opened at $7.55 on Friday. The business’s fifty day moving average price is $9.27 and its two-hundred day moving average price is $12.60. The company has a market capitalization of $357.55 million, a P/E ratio of -2.09 and a beta of 0.77. Aerie Pharmaceuticals, Inc. has a 1-year low of $6.67 and a 1-year high of $21.30.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Thursday, November 4th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.10). Aerie Pharmaceuticals had a negative net margin of 159.85% and a negative return on equity of 1,531.00%. The business had revenue of $29.31 million for the quarter, compared to the consensus estimate of $29.13 million. During the same period in the previous year, the firm earned ($0.65) EPS. Equities research analysts predict that Aerie Pharmaceuticals, Inc. will post -3.26 earnings per share for the current year.

Several analysts recently issued reports on the company. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating and set a $12.00 price target on the stock. in a report on Monday, November 15th. Needham & Company LLC started coverage on Aerie Pharmaceuticals in a report on Friday, December 17th. They issued a “buy” rating and a $22.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $21.33.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L.

Featured Article: What is a Swap?

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.